{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-028602","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2026-07-16T11:00:46+00:00","discovered_at":"2026-07-16T11:05:00.281889+00:00","generated_at":"2026-07-16T11:05:06.147945+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Insmed reports positive 12-month OLE data for TPIP in PAH; sustained improvement across endpoints","bullets":["6MWD improved +55.7m (TPIP continued) and +54.1m (placebo crossed) from baseline at Month 12.","NT-proBNP reduced ~60% in both groups; WHO Functional Class I/II achieved in ~80% of patients.","REVEAL Lite 2.0 score improved 2.0 points (TPIP continued) and 1.4 points (placebo crossed); ~65% low-risk.","TPIP well-tolerated with no new safety signals; most common TEAEs: headache (28.6%), cough (15.4%).","Phase 3 PALM-PAH trial initiated; topline Phase 2b results previously reported June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-028602","json":"https://secwatch.observer/filing/0001140361-26-028602.json","markdown":"https://secwatch.observer/filing/0001140361-26-028602.md","text":"https://secwatch.observer/filing/0001140361-26-028602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/0001140361-26-028602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126028602/ef20078093_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-16T11:05:06.147945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}